Xeljanz Recommended Dosage For Ulcerative Colitis Patients May Increase Risk Of Pulmonary Embolism

FDA Is Reviewing Safety Of Xeljanz 10 mg Twice-Daily Dose Of This JAK In­hibitor, According to February 2019 News Reports   (Posted by Tom Lamb at DrugInjuryWatch.com)   Pfizer's Xeljanz (tofacitinib) is approved by the FDA for treatment of adult patients with moderately to severely active ulcerative colitis (UC).  It is also indicated for treatment of adult patients with moderately to severely active rheumatoid or active psoriatic arthritis who have had an inadequate response to certain other drugs. There appears to be a somewhat "under the radar" drug-safety issue with the 10 mg twice daily recommended dosage of Xeljanz for patients with ulcerative colitis (UC), according to this February 20, 2019 article, "FDA cites an ‘ongoing review’ for Pfizer’s blockbuster Xeljanz, with implications for the class", published by Endpoint News [free subscription required].  From this article, by reporter John Carroll, we…

Read more detail on Recent Injury and Accident Law posts –

Related news:

This entry was posted in Injury & Accident Law and tagged , , , , , , , , , . Bookmark the permalink.

Leave a Reply